CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics

January 23, 2024

https://www.globenewswire.com/news-release/2024/01/23/2813910/0/en/CENTOGENE-and-The-Michael-J-Fox-Foundation-Announce-Research-Project-to-Validate-Genetic-Risk-Factors-of-Parkinson-s-Disease-Using-Multiomics.html

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Jan. 23, 2024 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, and The Michael J. Fox Foundation for Parkinson’s Research (MJFF), a non-profit organization dedicated to finding a cure for Parkinson’s disease (PD), today announced a research project to accelerate research on genetic risk factors associated with PD, specifically targeting the role of variants in the GBA (glucosylceramidase beta) gene.

Read more at globenewswire.com

Related news for (CNTG)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.